Vol 53, No 1 (2022)
Original research article
Published online: 2022-02-25

open access

Page views 5122
Article views/downloads 312
Get Citation

Connect on Social Media

Connect on Social Media

Role of tumor necrosis factor-alpha–308 G/A and interleukin-10 promotor–592 C/A polymorphisms in adult immune thrombocytopenic purpura

Amani Fouad Sorour1, Ahmed Mohamed Lotfy Bedewy2, Irene Lewis Mikhael2, Asmaa Ahmed Abd El-Aziz El-Zokm2, Samar Mahmoud Masoud Aboelsaad1, Salma Alaa Eldin Imbaby1
Acta Haematol Pol 2022;53(1):58-65.


Introduction: Immune thrombocytopenia (ITP) pathogenesis has been related to cytokine imbalance, which is controlled genetically with gene polymorphisms. The correlation of the interleukin (IL)-10 gene and tumor necrosis factor alpha (TNF-α) polymorphisms with ITP susceptibility has been previously investigated, but the association with clinical and prognostic parameters remains unclear. Material and methods: To investigate the relation between IL-10-592 C/A and TNF-α-308 G/A gene polymorphisms and their clinical significance in adult patients with ITP. This study was conducted on 40 ITP patients and 40 control individuals. The IL-10-592 C/A polymorphism was genotyped by the polymerase chain reaction-restriction fragment length polymorphism method and the TNF- α-308 G/A polymorphism by amplification refractory mutation system analysis. Results: The TNF-α-308 G/A polymorphism was significantly associated with low platelet count, wet purpura, higher bleeding score, higher incidence of complications, and lack of response to steroid therapy. The IL-10-592 C/A polymorphism was not significantly associated with any of these parameters. Conclusion: We found a significant association between the TNF-α-308 G/A polymorphism and several clinical parameters, which suggests a probable role in the prognosis among adult ITP patients.

Article available in PDF format

View PDF Download PDF file


  1. El Ghannam D, Fawzy IM, Azmy E, et al. Relation of interleukin-10 promoter polymorphisms to adult chronic immune thrombocytopenic purpura in a cohort of Egyptian population. Immunol Invest. 2015; 44(7): 616–626.
  2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11): 2386–2393.
  3. Schulze H, Gaedicke G. Immune thrombocytopenia in children and adults: what's the same, what's different? Haematologica. 2011; 96(12): 1739–1741.
  4. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010; 24(1): 249–273.
  5. Negi RR, Bhoria P, Pahuja A, et al. Investigation of the possible association between the HLA antigens and idiopathic thrombocytopenic purpura (ITP). Immunol Invest. 2012; 41(2): 117–128.
  6. Moolman-Smook J, De Lange W, Corfield V, et al. Expression of HCM causing mutations: lessons learnt from genotype-phenotype studies of the South African founder MYH7 A797T mutation. J Med Genet. 2000; 37(12): 951–956.
  7. Qidwai T, Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol. 2011; 74(6): 522–547.
  8. Hajeer AH, Hutchinson I. Influence of TNFα gene polymorphisms on TNFα production and disease. Hum Immunol. 2001; 62(11): 1191–1199.
  9. Tekeli O, Turacli ME, Egin Y, et al. Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma. Mol Vis. 2008; 14: 1815–1818.
  10. Akar N, Hasipek M. Tumour necrosis factor-alpha gene polymorphism (-308 G-A) in Turkish pediatric thrombosis patients. Turk J Haematol. 2002; 19(1): 39–41.
  11. Najafi S, Moqadam IF, Mohammadzadeh M, et al. Interleukin-10 genepolymorphisms in recurrent aphthous stomatitis. Immunol Invest. 2014; 43(4): 405–409.
  12. Movahedi M, Mahdaviani S, Rezaei N, et al. IL-10, TGF-ß, IL-2, IL-12, and IFN-γ cytokine gene polymorphisms in asthma. J Asthma. 2009; 45(9): 790–794.
  13. Liu J, Song B, Bai X, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer. 2010; 10: 456.
  14. Ou Y, Yang Y, Xiang X, et al. Relationship between the IL-10 (−1082 A/G) polymorphism and the risk of immune/idiopathic thrombocytopenic purpura: A meta-analysis. Cytokine. 2020; 125: 154820.
  15. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88(1): 3–40.
  16. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168–186.
  17. George JN AD, Leung LL, Tirnauer JS. Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis. UpToDate Walthma, Massachusetts 2018. https://www.uptodate.com/contents/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis (January 1, 2021).
  18. Wei Yu, Ji Xb, Wang Yw, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016; 127(3): 296–302; quiz 370.
  19. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11): 2386–2393.
  20. Bergmann AK, Grace RF, Neufeld EJ. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol. 2010; 89 Suppl 1: S95–103.
  21. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003; 349(23): 2201–2210.
  22. Núñez C, Alecsandru D, Varadé J, et al. Interleukin-10 haplotypes in celiac disease in the Spanish population. BMC Med Genet. 2006; 7: 32.
  23. Eskdale J, Kube D, Tesch H, et al. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics. 1997; 46(2): 120–128.
  24. Popa C, Netea MG, van Riel PL, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007; 48(4): 751–762.
  25. Beutler BD, Cohen PR, Beutler B, et al. The complex regulation and biology of TNF (cachectin). Crit Rev Oncog. 1990; 2(1): 9–18.
  26. El Sissy MH, El Sissy AH, Elanwary S. Tumor necrosis factor-α -308G/A gene polymorphism in Egyptian children with immune thrombocytopenic purpura. Blood Coagul Fibrinolysis. 2014; 25(5): 458–463.
  27. Satoh T, Pandey JP, Okazaki Y, et al. Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004; 124(6): 796–801.
  28. Saitoh T, Kasamatsu T, Inoue M, et al. Interleukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients. Int J Lab Hematol. 2011; 33(5): 526–532.
  29. Wu KH, Peng CT, Li TC, et al. Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura. Br J Haematol. 2005; 128(6): 849–852.
  30. Okulu E, İleri T, Koşan Çulha V, et al. The role of tumor necrosis factor-alpha -308 G/A and transforming growth factor-beta 1 -915 G/C polymorphisms in childhood idiopathic thrombocytopenic purpura. Turk J Haematol. 2011; 28(3): 170–175.